Lyme disease vaccine nears approval after successful clinical trials

The fight against Lyme disease is approaching a significant breakthrough with the successful completion of clinical trials for a new vaccine. Developed through a collaboration between pharmaceutical companies Pfizer and Valneva, the vaccine has advanced to the registration process, signaling a potential new era in preventing the tick-borne illness.

This innovative vaccine works by stimulating the production of antibodies against a specific outer surface protein of the Borrelia bacteria. When an infected tick bites a vaccinated individual, these antibodies neutralize the bacteria within the tick itself, preventing transmission to the human host. The vaccine is designed to protect against six of the most prevalent Borrelia strains found in Europe and North America, addressing a key challenge given the diversity of Lyme-causing bacteria across regions.

“

The vaccine against Lyme disease has successfully passed clinical trials, and the registration process is currently underway, which may take time.

In Lithuania, where the vaccine's development is being closely watched, public health officials are also emphasizing the importance of tick prevention. The National Public Health Center (NVSC) reports an increase in tick-borne illnesses, with 27 cases of tick-borne encephalitis and 1,398 cases of Lyme disease recorded between January and May this year. Specialists attribute the rising tick activity not necessarily to a population boom, but to favorable conditions created by climate change, including milder winters and longer warm seasons, leading to ticks being active for extended periods. They advise regular lawn mowing, removal of leaf litter, and the use of repellents when spending time outdoors.

While the vaccine has shown promising results, with Phase III trials involving over 9,000 participants demonstrating a roughly 73% reduction in symptomatic Lyme disease risk without significant safety concerns, it is not yet approved for use. The registration process with European and U.S. drug regulatory bodies is ongoing and may take time. The NVSC confirmed the vaccine's successful clinical trials, noting that the registration phase is the next step before it can become available to the public.

“

Ticks prefer damp, shady places with tall grass, dense bushes, leaf litter, and poorly maintained greenery. To reduce their numbers around homes, it is recommended to regularly mow the lawn, remove last year's leaves and plant debris, thin dense bushes, and tidy up areas around recreation spots and children's playgrounds. When in nature or working in the yard, it is worth using tick repellents, wearing light-colored clothing that covers the body, and carefully examining yourself, children, and pets after returning home.